| 发明名称 | Method of treating prostate cancer with GnRH antagonist | ||
| 摘要 | The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. | ||
| 申请公布号 | US9579359(B2) | 申请公布日期 | 2017.02.28 |
| 申请号 | US201314139922 | 申请日期 | 2013.12.24 |
| 申请人 | FERRING B.V. | 发明人 | Olesen Tine Kold;Persson Bo-Eric;Cantor Per;van der Meulen Egbert A;Jensen Jens-Kristian Slott |
| 分类号 | A61K31/33;A61K38/09;A61K38/08 | 主分类号 | A61K31/33 |
| 代理机构 | Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | 代理人 | Finnegan, Henderson, Farabow, Garrett & Dunner, LLP |
| 主权项 | 1. A method of treating prostate cancer in a subject with a reduced likelihood of causing a testosterone spike or other gonadotrophin releasing hormone (GnRH) agonist side-effect comprising: administering an initial dose of 160-320 mg of degarelix to the subject, wherein the initial dose is administered as two subcutaneous injections; and administering a maintenance dose of 60-160 mg of degarelix to the subject once every 20-36 days thereafter, wherein the maintenance dose results in a testosterone suppression below 0.5 ng/mL; thereby treating prostate cancer in the subject with a reduced likelihood of causing a testosterone spike or other GnRH agonist side effect. | ||
| 地址 | Hoofdorp NL | ||